Bovine herpesvirus type 1 (BHV-1) U L 49.5 inhibits transporter associated with antigen processing (TAP) and down-regulates cell-surface expression of major histocompatibility complex (MHC) class I molecules to promote immune evasion. We have constructed a BHV-1 U L 49.5 cytoplasmic tail (CT) null and several U L 49.5 luminal domain mutants in the backbone of wildtype BHV-1 or BHV-1 U L 49.5 CT-null viruses and determined their relative TAP mediated peptide transport inhibition and MHC-1 down-regulation properties compared with BHV-1 wt. Based on our results, the U L 49.5 luminal domain residues 30-32 and U L 49.5 CT residues, together, promote efficient TAP inhibition and MHC-I down-regulation functions. In vitro, BHV-1 U L 49.5 D30-32 CT-null virus growth property was similar to that of BHV-1 wt and like the wt U L 49.5, the mutant U L 49.5 was incorporated in the virion envelope and it formed a complex with gM in the infected cells.
Introduction
Bovine herpesvirus-1 (BHV-1) is an important cattle pathogen responsible for a wide variety of clinical diseases, including conjunctivitis and upper respiratory tract infection known as infectious bovine rhinotracheitis (IBR), reproductive tract lesions and abortion in pregnant cows, and systemic infection in the newborn [1, 2, 3] . In addition, BHV-1 has been recognized as an important component of the bovine respiratory disease (BRD) complex [3, 4] . Normally, proteosomally processed viral proteins yield peptides that bind to TAP heterodimer, consisting of the subunits TAP1 and TAP2 [5, 6, 7] . Following viral peptide binding, the TAP1/TAP2 heterodimer undergoes conformational changes [5, 6, 7] . Subsequently, peptides are transported into the ER and loaded onto MHC-I molecules to form MHC/peptide complexes which are transported to and presented on the cell surface [8, 9] . However, in BHV-1-infected cells, U L 49.5 (BHV-1 homolog of envelope glycoprotein gN) binds to TAP, interferes with its peptide transport function and also degrades the TAP [10, 11] . Consequently, BHV-1 interferes with the MHC class I antigen presentation pathway and during the initial phase of viral infection, escapes host cellular immune surveillance and elimination [11] [12] [13] [14] [15] . Modified live vaccines (MLV) against BHV-1 including genetically engineered gE-deleted marker vaccines are being used for vaccination against BHV-1. However, problems associated with BHV-1 infection in the vaccinated animals exist, especially in the feedlot. Since both the traditional and gE-deleted MLVs have wildtype U L 49.5, these vaccines like the wild-type virus, are transiently immunosuppressive. Therefore, there is a need for further improvement of the current MLVs [16] [17] [18] [19] .
Alphaherpesvirus U L 49.5 (gN) and gM homologs are associated with cellular and virion membranes and the gN homologs form complexes with envelope glycoprotein gM [20] [21] [22] . BHV-1 U L 49.5 predicted ORF (Fig. 1A) is composed of an N-terminal signal sequence of 22 amino acids (aa), an extracellular luminal domain of 32 aa, a transmembrane (TM) domain of 25 aa, and a short cytoplasmic tail (CT) of 17 aa [10, 22, 23] . Previous results have shown that a BHV-1 U L 49.5 CT-truncated virus lacking the cytosolic 17 amino acids no longer degraded bovine TAP molecules yet retained the TAP inhibition and MHC-I down-regulation functions [15] . This suggests that the BHV-1 U L 49.5 luminal domain or TM domain is associated with the TAP inhibition function.
Recently, using N-terminal and C-terminal truncated versions of BHV-1 U L 49.5 expressed in a Baculovirus expression vector system, it was shown that U L 49.5 luminal domain residues 23-32 and U L 49.5 cytoplasmic tail residues 94-96 are both essential for U L 49.5-mediated degradation of human TAP [24] . However, U L 49.5 luminal domain residues 28-32 alone are sufficient for human TAP inhibition and down-regulation of human MHC-I surface expression [24] . The goal for this study was to i) identify the exact U L 49.5 residues critical for bovine TAP inhibition and bovine MHC-I down-regulation in the context of BHV-1 virusinfected Madin-Darby bovine kidney (MDBK) cells, and ii) determine the effect of U L 49.5 mutations on U L 49.5/gM complex formation and gM processing. We constructed BHV-1 U L 49.5 luminal domain mutants, with a short sequence deletion, using a BHV-1 U L 49.5 cytoplasmic tail (CT) null virus or wt BHV-1 as a backbone and analyzed their TAP inhibition and MHC-I molecule surface expression properties in infected MDBK cells relative to wt BHV-1. The results demonstrate that U L 49.5 residues 30 to 32 are essential for the BHV-1 U L 49.5-mediated TAP inhibition/MHC-I down-regulation function. However, U L 49.5 CT residues are required for efficient TAP inhibition/ MHC-I down-regulation. The mutant U L 49.5 lacking luminal domain residues 30-32 and the entire cytoplasmic tail is incorporated in the virion envelope and it formed a complex with gM in the infected cells.
Materials and Methods

Cells and virus strain
The MDBK cell line was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5-10% heatinactivated fetal bovine serum (FBS). The BHV-1 Cooper (Colorado-1) strain, obtained from the American Type Culture Collection (Manassas, VA) was propagated and titrated in MDBK cells as previously described [25] .
Plasmids and bacterial strains
Vector pGEX-4T-2 (GE healthcare) and E. coli strain BL21 were used to express BHV-1 U L 49.5-GST or bovine TAP1-GST fusion proteins. E. coli strain DH10B was used to maintain all the infectious BHV-1 BAC clones. E. coli strain SW105 (kindly provided by Dr. Copeland) was used for Red recombination.
Antibodies
Chicken anti-Calreticulin (ER) polyclonal Ab (ab14234, Abcam), biotinylated donkey anti-rabbit IgG (ab6801, Abcam), HRP-conjugated donkey anti-rabbit IgG (Cat. 31458, Thermo), phycoerytrin (PE)-conjugated donkey anti-goat antibody (F0107, R&D), Alexa Flour (350)-conjugated donkey anti-chicken Ab (Invitrogen), Alexa flour 488-conjugated donkey anti-goat Ab (Molecular Probes), Alexa flour 594-conjugated donkey anti-rabbit Ab (Molecular Probes), mouse anti-MHC I Ab (H58A, VMRD), and FITC-conjugated rat anti-mouse IgG (ebioscience) were purchased from the respective commercial sources.
Production of anti-BHV-1 U L 49.5-, gM-and anti-bovine TAP1-specific polyclonal sera i)
Anti-BHV-1 gM-specific antibody. A peptide corresponding to the predicted amino acid (aa) residues 191-205 ([H]-QAVHALRERSPRAHRC-OH) of BHV-1 gM was synthesized and conjugated to polyethylene glycol as described earlier [26] [27] and used to immunize New Zealand white rabbits (Cocalico Biologicals) to generate anti-BHV-1 gM serum.
ii) Anti-BHV-1 U L 49.5-specific antibody. The DNA fragment corresponding to U L 49.5 amino acid residues 23 to 60 (Genbank Accession No. AJ004801) was cloned into pGEX-4T-2 vector and expressed in E. coli BL21 as a GST fusion protein.
The U L 49.5-specific peptide was purified using a glutathionesepharose column followed by thrombin protease cleavage and used to immunize rabbits (Cocalico Biologicals) as described earlier [27] .
iii) Anti-bovine TAP1-specific antibody. The predicted amino acid residues 117 to 167 and residues 351 to 415 (Accession No. AAY34698) of bovine TAP1 were amplified by PCR, cloned into Vector pGEX-4T-2, expressed as GST fusion proteins, and purified to immunize rabbits and goats as described above.
Cell transfection and generation of U L 49.5 expressing cell line
To generate a U L 49.5 expressing cell line, first the entire BHV-1 U L 49.5 ORF coding region was amplified from the wild type BHV-1 Cooper strain genomic DNA by PCR and cloned into the eukaryotic expression vector, pEF6/V5-His TOPO (Invitrogen). Positive clones containing U L 49.5-specific sequences were identified by PCR and sequencing of the U L 49.5 ORF coding region. One positive U L 49.5-pEF6/V5-His clone DNA was transfected into MDBK cells by Lipofectamine (Invitrogen) as described earlier [27] . Forty-eight hours after transfection, confluent cells were treated with trypsin and diluted 5-fold in DMEM containing 10 mg/ml of Blastcidin (Invitrogen) and plated in 25 cm 2 flasks. The Blastcidin concentration was decreased to 5 mg/ml after 7 days, and thereafter the medium was replaced every 3 days until the distinct Blasticidin-resistant colonies developed. Blastcidinresistant clones were then isolated and analyzed for U L 49.5 expression by indirect immunofluorescence (IF) and immunoprecipitation assays (Fig. S2) .
Radiolabelling of mock-or virus-infected MDBK cell proteins, SDS-PAGE and immunoprecipitation/ immunoblotting analysis [ 35 S] methionine-cysteine labeling of the mock-or virus-infected MDBK cells was performed as described earlier [28, 29] . Cell lysates and immunoprecipitates were denatured at 100uC in reducing sample buffer containing b-mercapthoethanol for the U L 49.5 samples, and separated in a 5,20% linear gradient sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) [23] . However, for gM and TAP1 analyses, cell lysates and immunoprecipitates were incubated at 56uC in reducing sample buffer with 100 mM Dithiothreitol (DTT) and then loaded on a 5,20% linear gradient or 10% SDS-PAGE respectively [22, 23, 28] .
Construction of BHV-1 U L 49.5 cytoplasmic tail null virus (BHV-1 U L 49.5 CT-null BAC)
We followed a two-step Red-mediated mutagenesis protocol as described earlier by Tischer et al [30] to construct a U L 49.5 cytoplasmic tail null virus. Briefly, primers for U L 49.5-CT nullforward (for) and U L 49.5-CT null-reverse (rev) were designed to delete 7 nucleotides (nt) of U L 49.5 ORF (238 to 244, AGGCTCA) and to mutate the nt 246-247 (GG) to AA (Fig. S1, table 1) . The PCR amplified I-SceI/aphAI cassette was digested with Dpn I, purified and electroporated together with pBAD-I-SceI DNA into SW105 competent cells harboring pBHV-1 WT BAC for 1 st recombination as described earlier [30, 31, 32] . Several kanamycinsensitive colonies were obtained after the 2 nd recombination. Finally, positive pBHV-1 BAC U L 49.5 CT-null colonies were identified by PCR and sequencing of the U L 49.5 ORF in the putative mutant colonies. The BAC-excised BHV-1 U L 49.5 CT-null virus was generated from a pBHV-1 BAC U L 49.5 CT-null clone by Cre-mediated BAC excision as described earlier [30] [31] [32] .
BAC mutagenesis to incorporate short deletions or alanine substitutions within UL49.5 luminal domain
As shown in nd recombination was performed as described above. Reconstituted BAC containing or BAC-excised mutant viruses were then generated as described earlier [30, 31, 32] . BAC-excised U L 49.5 mutant viruses were plaque purified and designated as BHV-1U L 49.5D30-32, U L 49.5 30AAA32, UL49.5D30-32 CTnull, U L 49.5 30AAA32 CT-null, U L 49.5D37-40 CT-null, and U L 49.5D43-46 CT-null, respectively. Viral growth kinetics and plaque size determination
One step growth curve assays were performed as described earlier [25, 33] . Average plaque size was calculated by measuring 50 randomly selected plaques for each mutant virus (under a microscope with a graduated ocular objective).
TAP1 and U L 49.5 intracellular staining and laser scanning confocal microscopy MDBK cells grown on permanox chamber slides (Cole-Parmer) were infected with wt BHV-1 or BHV-1 U L 49.5 mutant viruses. Cells were fixed at different times post-infection with freshly prepared 1% paraformaldehyde in PBS, permeabilized with FACS permeabilizing solution, and blocked with 2% IgG free bovine serum albumin. The cells were incubated (for 60 minutes) with a cocktail of goat antibovine TAP 1 (1:800), rabbit anti-U L 49.5 (1:3,200) and chicken anticalreticulin (ER) antibodies (1:3,200), washed and subsequently stained (for 15 min) with a cocktail of Alexa flour 488-conjugated donkey anti-goat (1:2,000), Alexa 350-conjugated donkey antichicken (1:2,000), and Alexa flour 594-conjugated donkey anti-rabbit antibodies (1:2,000). After 5 washes, coverslips were mounted onto slides and examined with a Zeiss LSM510 laser scanning confocal microscopy using 206 and 406 objectives. Cellular ER-, bovine TAP1-and U L 49.5-specific labeling was excited at laser wavelengths of 410 nm, 517 nm, and 617 nm respectively.
Analysis of peptide transport in the BHV-1 U L 49.5 mutants-infected cells
MDBK cells grown on 6-well plate were infected at a MOI of 10 with BHV-1 wt, BHV-1 U L 49.5 CT-null and various U L 49.5 luminal domain mutant viruses. At different time-points (2, 5, and 8 hpi), the cells were trypsinized, permeabilized, and incubated with 5 ml of Phycoerythrin-conjugated mouse anti-calreticulin (anti-ER) MAb (Clone FMC 75, Abcam) and the FITCconjugated synthetic peptide, SVNKTERAY, in the absence and presence of ATP (10 mM, Sigma) for 20 min at 37uC in the dark [11, 34] . The cells were fixed after three washes and analyzed for fluorescence intensity by a FACS Calibur flow cytometer. At least 30,000 gated events based on forward and side scatters and pulse width were analyzed using Summit Data Acquisition and Analysis software (DakoCytomation). The mock infected MDBK cells served as a control.
Detection of MHC-I expression on the infected cell surface by FACS
Approx. 10 6 of MDBK cells either mock infected or infected (1 MOI) with BHV-1 wt, BHV-1 U L 49.5 CT-null, or individual BHV-1 mutant virus were collected at 12 or 18 hpi, blocked with IgG free BSA, and incubated (for 20 min) with mouse anti-bovine MHC I Ab. After PBS washes, cells were incubated with 5 ml of FITCconjugated rat anti-mouse Ab and fixed with 2% formalin and then analyzed by flow cytometer. The stained cells were gated based on forward and side scatters and pulse width. At least 30,000 gated events were analyzed using Summit Data Acquisition and Analysis Software (DakoCytomation) as previously described [35] . MDBK cells infected similarly with the respective viruses were stained by FITC-conjugated mouse IgG2a and used as the isotype controls.
Results
Construction and characterization of BHV-1 UL49.5 CT-null virus and UL49.5 luminal domain mutants
We constructed a BHV-1 U L 49.5 CT-null mutant virus by deletion of two predicted amino acid residues 80RL81 encoded by nt 238-AGGCTCA-244 (Fig. 1A and Fig. S1 ). In addition, nt 246GG247 were mutated to AA thereby incorporating a strong stop codon, TAA immediately downstream of the predicted aa residue 79F (Fig. 1A and Fig. S1 ).
Based on an alignment of predicted amino acid sequences of U L 49.5 luminal domains of several animal alpha herpesviruses; BHV-1, pseudorabiesvirus (PRV, Accession No. U38547.1), equine herpesvirus 1 type (EHV-1, Accession No. AY665713.1), equine herpesvirus type 4 (EHV-4, Accession No. NC_001844), and canine herpesvirus (CHV, Patent EPO 910406), we noticed that a BHV-1 luminal domain motif U L 49.5 30-RXEXXXX-FW-XXXCXXXG-46 is conserved within the corresponding U L 49.5 luminal domains of several alpha herpesviruses (Fig. 1B) . To determine whether any of these conserved sequences are functionally important for TAP inhibition, we designed and constructed BHV-1 U L 49.5 luminal domain mutants (U L 49.5D30-32, U L 49.5D37-40 and U L 49.5D43-46) initially, in the BHV-1 U L 49.5-CT null backbone (Fig. 1C) . To determine the role of residues 30-32 alone in TAP inhibition and TAP degradation, we constructed both U L 49.5D30-32 and alanine exchanged (U L 49.5 30AAA32) mutants, later, in the BHV-1 wt backbone (Fig. 1D) .
BAC excised BHV-1 U L 49.5 mutant viruses were analyzed by immuno-precipitation and/or immunoblotting to determine molecular mass and level of mutant U L 49.5 expression, incorporation of the mutant U L 49.5 in the envelope and effect of U L 49.5 mutation on gM processing or U L 49.5/gM interaction. As shown in Figure 2A , relative to wt U L 49.5 (approx. molecular mass 10 kDa), molecular mass of the CT-null U L 49.5 is approx. Fig. 2) . Importantly, all mutant U L 49.5 proteins were incorporated into their respective virion envelopes (Fig. 2) . Results of immunoprecipitation using U L 49.5-or gM-specific rabbit polyclonal antibodies showed that i) amounts of wt and mutant U L 49.5 CT-null, U L 49.5D30-32 CT-null, U L 49.5D43-46 CT-null, and U L 49.5D37-40 CT-null) immunoprecipitated by anti U L 49.5 antibody in each case were very similar (Fig. 3) , ii) the amount and molecular mass of mature gM coimmunoprecipitated by the anti U L 49.5 antibody from infected cell lysates of BHV-1 wt, BHV-1 U L 49.5 CT-null, BHV-1 U L 49.5D30-32 CTnull, and BHV-1 U L 49.5D43-46 CT-null viruses were very similar but in the case of BHV-1 U L 49.5D37-40 CT-null, the amount of processed (mature) gM coimmunoprecipitated was reduced (Fig. 3) , and iii) consistent with the latter results, with the exception of BHV-1 U L 49.5D37-40 CT-null, anti gM antibody coimmunoprecipitated similar amounts of U L 49.5 from the all the virus-infected cell lysates. In the case of BHV-1 U L 49.5D37-40 CT-null, the amount of U L 49.5 coimmuno-precipitated was slightly reduced and additionally, there was an increase in the amount of unprocessed gM (pgM) (Fig. 3) .
Taken together, these results indicated that the mutant viruses have essentially normal U L 49.5 expression and all but one mutant (U L 49.5D37-40 CT-null) have a normal gM processing and U L 49.5/gM interaction. The BHV-1 U L 49.5D37-40 CT-null virus has slightly defective gM processing and U L 49.5/gM interaction.
Growth characteristics of reconstituted U L 49.5 mutant viruses in vitro in MDBK cells
The results of average plaque sizes ( Figure 4A ) and one step growth kinetics ( Figure 4B) showed that all BHV-1 U L 49.5 mutants had virtually similar plaque sizes and growth kinetics when compared with BHV-1 wt.
Peptide transport in BHV-1 U L 49.5 mutant virus-infected cells
Peptide transport was assessed, in the presence (Fig. 5A and B) and absence of ATP (data not shown), in mock-infected MDBK cells and MDBK-U L 49.5
+ cells or infected with BHV-1 wt, BHV-1 U L 49.5 CT-null and individual BHV-1 U L 49.5 mutant viruses. At 5hpi the effect of U L 49.5 mutations on peptide transport in BHV-1 U L 49.5 mutant virus-infected cells relative to BHV-1 wtinfected cells was noticeable (Fig. 5A ), but the effects were more prominent at 8 hpi (Fig. 5B) . Relative to peptide transport in BHV-1 wt-infected MDBK cells at 8hpi, peptide transport in cells infected with: i) BHV-1 U L 49.5D30-32 and BHV-1 U L 49.5 30AAA32 was increased 4 fold (23% and 27% inhibition, respectively versus 84% inhibition for the wt; P,0.01) ii) BHV-1 U L 49.5 CT-null was increased 2.5 fold (63% inhibition versus 84% for the wt; P,0.05), and iii) BHV-1 U L 49.5D30-32 CT-null or BHV-1 U L 49.5 30AAA32 CT-null was increased to approx. 6 folds (7% and 10% inhibition, respectively versus 84% for the wt; P,0.01) (Fig. 5B) . Since there was also an additional 1.2-1. 30AAA32 cells (7%/10% versus 23%/27% inhibition, respectively) (Fig. 5) , the increase in peptide transport due to the U L 49.5 CT sequence deletion alone was also significant (P,0.05). As expected, in the absence of ATP there was no peptide transport in wt and mutant viruses-infected MDBK cells (data not shown).
Regardless of BHV-1 U L 49.5 D30-32 or BHV-1 U L 49.5D30-32 CT-null or BHV-1 U L 49.5 CT-null virus infection, at 8hpi, peptide transport in infected MDBK U L 49.5 + cells (Fig. S2 ) was inhibited to almost wt U L 49.5 level (,90%) (Fig. 5B) . Therefore, the relative increase in peptide transport in MDBK cells infected with BHV-1 U L 49.5 mutants with residues 30-32-deleted or substituted with alanine and BHV-1 U L 49.5 CT-null virus is due to the lack of U L 49.5 residues important for TAP mediated peptide transport function.
MHC class I cell-surface expression in BHV-1 U L 49.5 mutants-infected cells
As shown in Fig. 6A , compared with MHC-I cell surface expression in mock-infected MDBK cells, there was reduced MHC-1 expression in cells infected with BHV-1 wt and BHV-1 U L 49.5 CT-null viruses but not when cells were infected with BHV-1 U L 49.5 D30-32 CT-null virus (Fig. 6A) . As shown in Figure 6B , compared with BHV-1 wt-infected MDBK cells, MHC-I surface expression in: i) BHV-1 U L 49.5D30-32-and BHV-1 U L 49.5 30AAA32-infected MDBK cells was increased 2 fold (74.3% and 75.0%, respectively versus 36.2% for the wt; P,0.01) ii) BHV-1 U L 49.5 D30-32 CT-null-and BHV-1 U L 49.5 30AAA32 CT-null-infected MDBK cells was increased 2.5 fold (88.6% and 89.1%, respectively versus 36.2% for the wt; P,0.01) and iii) BHV-1 U L 49.5 CT-null-infected cells was increased by 1.3 fold (49.6% versus 36.2% for the wt; P,0.05). Since a similar 1.2-1.3 fold increase in MHC-I surface expression was also obtained in BHV-1 U L 49.5D30-32 CT-null-/BHV-1 U L 49.5 30AAA32 CTnull-compared with BHV-1 U L 49.5D30-32/BHV-1 U L 49.5 30AAA32 -infected cells (88.6%/89% versus 74.3%/75%), the increase in MHC-I expression due to the deletion of U L 49.5 CT sequences alone was also significant (P,0.05).
In MDBK U L 49.5 + cells, regardless of BHV-1 U L 49.5 CT-null or BHV-1 U L 49.5D30-32 CT-null virus infection, MHC-I cellsurface expression was down-regulated like in wt BHV-1-infected MDBK cells (Fig. 6B) . Therefore, the relative increase in MHC-I surface expression observed for the mutant viruses is due to the effect of specific U L 49.5 mutation(s) and is consistent with the peptide transport data obtained for respective mutants with wt or U L 49.5 CT-null backgrounds. (Fig. 8) . Nevertheless, at 6 hpi minor amounts of TAP1 were detectable in the ER of BHV-1 wt-infected MDBK cells which colocalized with U L 49.5 (data not shown).
Considering the TAP1 degradation, peptide transport, MHC-I down-regulation, and U L 49.5-TAP1 co-localization data, we can conclude that TAP1 and U L 49.5 residues 30-32 interaction in the ER is sufficient to inhibit TAP mediated peptide transport function. However, both U L 49.5 residues 30-32 and the U L 49.5 CT residues are required for maximum U L 49.5 inhibition of TAP function.
Discussion
Previous studies reported that following BHV-1 infection, TAP function was inhibited and as a consequence MHC-I surface expression was down-regulated [10, 11] . Our results from a recent study using a cytoplasmic tail truncated BHV-1 U L 49.5Am80 virus confirmed this finding and further demonstrated that BHV-1 U L 49.5Am80 did not degrade TAP molecules but retained TAP inhibition/MHC-I down-regulation functions in infected MDBK cells [15] . Therefore, the results implied that the functional domain required for TAP inhibition/MHC-I down-regulation maps elsewhere within U L 49.5. We then constructed two BHV-1 U L 49.5 transmembrane domain-deleted mutants (BHV-1 U L 49.5D55-66 and BHV-1 U L 49.5D 67-79) and determined that in both cases mutant U L 49.5 protein affected gM processing, and that both viruses had defective replication properties (data not shown). Additionally, we and others (Wiertz, personal communication) found that the mutant U L 49.5 versions lacking the transmembrane domain residues were not stable and were degraded (data not shown).
In this study, we constructed BHV-1 U L 49. Our results, in general, are in agreement with the results of Baculovirus expressed U L 49.5 in a transient expression system, especially with respect to U L 49.5 sequences important for TAP degradation [24] . However, our results differed with respect to TAP inhibition and MHC-I surface expression [24] . Our TAP inhibition results showed that even though U L 49.5 residues 30-32 are essential for TAP inhibition/MHC-I down-regulation functions, the fullest extent of U L 49.5 mediated TAP inhibition and MHC-I down-regulation additionally required the U L 49.5 cytoplasmic tail (CT) residues. In summary, the U L 49.5 residues 30-32 and U L 49.5 CT residues together inhibit peptide transport and down-regulate MHC-I cell surface expression.
Previously, Loch et al [24] reported that UL49.5 D23-32 neither inhibited nor degraded the TAP. Additionally, they reported that like the deletion of entire UL49.5 CT, deletion of two residues 95RG96 at the C terminus failed to induce proteosomal degradation of the TAP complex. Based on a conserved RXE motif in the corresponding U L 49.5/gN regions of BHV-1, EHV-1 and PRV, they predicted that the RXE motif might be important for these functions. Our results proved that the conserved RXE motif is indeed important for BHV-1 U L 49.5 TAP inhibition and TAP degradation functions. Previous studies predicted that wt U L 49.5 binds to TAP complex through its transmembrane domain, and that the binding of wt U L 49.5 leads to conformational arrest of TAP complex [24] . Subsequently, the luminal domain RXE motif signaling to the C-terminal residues 95RG96 across the ER membrane is necessary for triggering the degradation of the TAP complex. In this study, our results demonstrated that in the absence of either U L 49.5 luminal domain residues RXE or CT residues, TAP is not degraded. Therefore, both the sequence elements are equally important for the U L 49.5 mediated TAP degradation. Based on our results on TAP inhibition, it is also reasonable to predict that both the RRE motif and the CT may communicate in a similar fashion, noted above, to cause efficient U L 49.5 mediated TAP inhibition synergistically. However, they are not equally important for TAP inhibition because deletion of RXE motif had significantly higher TAP inhibition compared to CT-null. Interestingly enough, a BLAST search (program BLASTP 2.2.25+) of NCBI protein data bank revealed that similar RRE/RXE motif is highly conserved in a number of bacterial proteins important for ATP dependent enzymatic activity, transcriptional regulator, GTP and ATP binding proteins (Fig. 9) . Currently, it is not known whether the highly conserved RXE motifs in any of the proteins listed in Fig. 9 actually binds to ATP or are required for their ATP mediated functions. Recently, it was reported that BHV-1 U L 49.5 does not interfere with binding of ATP to TAP. However, EHV-1 U L 49.5 containing similar RXE motif inhibits TAP by interfering with ATP binding to TAP. It remains to be seen whether the RXE motif in EHV-1 U L 49.5 binds to ATP directly or interacts indirectly to prevent ATP binding to TAP. Loch et al [24] suggested that BHV-1 U L 49.5 inhibits TAP primarily by degrading TAP. While that might the case for the wt U L 49.5 where TAP is degraded, retention of significant TAP inhibition property of U L 49.5 lacking the CT where TAP is not degraded, requires an alternative mechanism of TAP inhibition. Taken together, our results in this study and since the motif is highly conserved in the enzymatically active proteins requiring ATP or in ATP binding proteins, we predict that in the absence of CT residues, U L 49.5 luminal domain RRE motif may interact with or compete in some fashion for ATP binding to TAP and blocks the peptide transport. This needs to be tested in future studies.
Both in BHV-1 and EHV-1, U L 49.5 (gN homolog) is not glycosylated but UL49.5/gM interaction is required for gM processing in the Golgi [21, 22, 23] . In PRV, gN is glycosylated but is not required for gM processing [20] . The analyses of mutant U L 49.5 proteins' interaction with gM and their effect on gM processing showed that only the mutant U L 49.5 D37-40 CT-null had slightly defective gM processing and mutant UL49.5/gM interaction. Recently, we have determined that alanine exchange mutation of BHV-1 U L 49.5 residue C42A affected mutant U L 49.5 interaction with the gM and gM processing in the Golgi but not the TAP inhibition function of U L 49.5 (Wei and Chowdhury, manuscript in preparation). Since U L 49.5 CT-null mediated TAP inhibition function was not affected due to the additional deletion of residues 37-40 and because residue C42 is important for gM binding and not for TAP inhibition (Wei and Chowdhury, manuscript in preparation), we conclude that U L 49.5 TAP inhibition and gM interaction domains are different and do not overlap.
Since the mutant U L 49.5D30-32 CT-null interaction with the gM and gM maturation was unaffected, and the mutant U L 49.5 was incorporated in the virion envelope, we interpreted that mutant U L 49.5 protein conformation was not affected. Results from a recent calf experiment indicated that immunogenicity of and cellular immunity against BHV-1 U L 49.5D30-32 CT-null mutant virus was enhanced when compared with wt BHV-1 (Wei and Chowdhury, in submission). Therefore, by incorporating these U L 49.5 mutations in a future BHV-1 marker vaccine we could improve the vaccine efficacy of the current BHV-1 gE-deleted marker vaccine. 
